Dr. M. Gopi Reddy, Vice President and Head of Corporate Quality Compliance and CQA at Sun Pharma, brings over 27 years of expertise to the forefront of pharmaceutical quality and compliance. With a rich background encompassing leadership roles in major companies like GSK, Glenmark Pharma, and Cipla, Dr. Reddy is a stalwart in managing diverse pharmaceutical formulations from solid dosages to biologics. Holding an M.Pharm and an MBA in Pharmaceutical Chemistry, his work ensures that Sun Pharma’s products meet rigorous international standards, exemplifying his commitment to maintaining the highest levels of quality assurance in the pharmaceutical industry. In this exclusive interview with Raja Aditya of NSH, Dr. Reddy shares insights into the evolving landscape of pharmaceutical quality and compliance.
Dr. Gopi Reddy, could you share a brief overview of your background and your current role at Sun Pharma?
I’m Gopi Reddy. I currently lead the Corporate Quality and Complaints department at Sun Pharma. My career spans around 28 years in the pharmaceutical industry, with a foundation in M.Pharmacy. My journey in quality management has taken me through several prestigious companies including Glenmark, Cipla, and Aurobindo, before joining Sun Pharma two years ago.
Initially starting in production, I advanced to roles such as site quality head and now, corporate quality and compliance. This path has endowed me with extensive experience in handling various regulatory inspections and in developing robust teams in quality and regulatory affairs.
Dr. Reddy, given your extensive experience in regulatory audits, could you elaborate on the regulatory challenges currently facing the biosimilars and biologics industry?
Over the past 28 years, I’ve encountered more than 100 regulatory inspections from esteemed bodies such as the US FDA, MHRA, EMA, ANVISA in Brazil, TGA in Australia, among others. This extensive experience underscores a significant evolution in the pharmaceutical industry, which I’ve witnessed firsthand over the last quarter-century. Initially, the industry’s focus was on achieving certifications such as ISO. However, back in the early 2000s, we lacked sophisticated labeling systems that are commonplace today. Since then, there has been substantial automation introduced within both quality and manufacturing systems.
The predominant challenge now lies in the commitment of management to maintain the high quality of people, products, and systems. As the product development process becomes more sophisticated, and as equipment capabilities and automation advance, the necessity for a skilled workforce becomes increasingly critical. Ensuring we have the right people in the right roles is a significant challenge we continue to face. It’s imperative that with the support of our training departments and through the commitment of our management, we align the right individuals with the correct skill sets to the appropriate products and roles. With this strategic alignment and commitment, we are well-prepared to successfully navigate any regulatory inspection.
As a leader in pharmaceutical quality compliance, what feedback do you receive on the quality assurance landscape, particularly regarding the shift towards automation?
As we delve deeper into automation across the pharmaceutical sector, we encounter increasingly complex challenges, particularly in sustaining the maintenance of these automated systems amidst rapid technological growth. Currently, the trend is moving strongly towards automation in areas such as manufacturing, quality control, and quality assurance. This shift from traditional paper-based systems to electronic media is substantial. Previously, our documentation—from SOPs to worksheets in QC and batch records—was manually handled. Now, we are transitioning to automated systems like Electronic Document Management Systems (EDMS) in documentation, Laboratory Information Management Systems (LIMS) in QC, and Enterprise Resource Planning (ERP) for material handling.
The rise of automation necessitates a corresponding enhancement in the skill sets of our personnel. There’s a pressing need for employees who not only understand the operational aspects but are also proficient in IT to effectively manage these advanced systems. Currently, we rely heavily on consultant services, which brings its own set of challenges. Many consultants come with a strong IT background but lack specific pharmaceutical expertise, which can lead to gaps in understanding and applying IT solutions effectively within pharmaceutical contexts.
Thus, a significant challenge for us is ensuring we have the right people who can bridge the gap between advanced IT and pharmaceutical operations. Ensuring our teams are equipped with the necessary IT skills and knowledge is crucial for the maintenance and successful integration of automation in our processes. This alignment is essential to sustain and enhance our automation efforts effectively.
Dr. Reddy, as global pharmaceutical standards continue to evolve, how do you see the integration of international quality standards impacting the industry, especially in India?
Thank you for the question. Recently, India has updated its Schedule M guidelines to align more closely with the regulatory expectations of the FDA and European countries. This revision is critical as it ensures that both small and large-scale manufacturing companies in India are prepared to meet these updated requirements. Regarding exports and regulatory compliance outside of India—specifically in regions like Europe, North America, and Latin America—it’s imperative for companies to continually monitor the evolving regulatory landscapes in these areas.
It’s crucial to establish systems that can keep track of new guidelines issued by international regulatory bodies such as the USFDA, MHRA, and EMA. Success on the global stage requires more than just a local presence; it demands adherence to international standards. Companies looking to expand globally must not only keep abreast of changes in regulatory guidelines and product development but also ensure these updates are continuously monitored and implemented by their teams. This strategic focus will help companies maximize their revenue and enhance their reputation across global markets.
How do you view the role of new analytical techniques in enhancing the quality assurance of biologics and biosimilars?
Biologics and biosimilars present unique challenges in quality control testing that differ significantly from those of small molecules. Techniques such as biosis and immunosis are crucial for managing microbial controls and chromatography in biologics. An important advancement in this area is the integration of automation technology, which can significantly reduce testing times. As we continue to navigate this field, it becomes imperative to focus on developing and refining methods specifically tailored to the needs of biologics and biosimilars to ensure their efficacy and safety.
